← Leaderboards
Ronald B Gartenhaus
Va Veterans Administration Hospital
$2,393,943
Attributed
$3,085,668
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $712.5K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,085,668 · 2
VA$0 · 3
By mechanism
R01$3,085,668 · 2
I01$0 · 3
Top collaborators
- Andrew M Evens5 shared
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaLymphomagenesisLarge Cell Diffuse Non-Hodgkin&AposPhosphotransferasesMolecularLymphomaNon-Hodgkin&AposMouse ModelToxic EffectIncidenceB-LymphocytesProteinsMalignant NeoplasmsSignal TransductionPhosphorylationTranslationsPathway InteractionsCellsSignal PathwayElderlyClinically RelevantAgingGenesOncogenic
Grant awards (23)
Molecular Characterization of elF4B$0
I01 · FY2025 · VA · contact PI
Molecular Characterization of elF4B$0
I01 · FY2024 · VA · contact PI
Molecular Characterization of elF4B$0
I01 · FY2023 · VA · contact PI
Lymphoma development in the elderly: Perturbed posttranscriptional regulation$0
I01 · FY2019 · VA · contact PI
Lymphoma development in the elderly: Perturbed posttranscriptional regulation$0
I01 · FY2019 · VA · contact PI
Lymphoma development in the elderly: Perturbed posttranscriptional regulation$0
I01 · FY2018 · VA · contact PI
Lymphoma development in the elderly: Perturbed posttranscriptional regulation$0
I01 · FY2017 · VA · contact PI
Lymphoma development in the elderly: Perturbed posttranscriptional regulation$0
I01 · FY2016 · VA · contact PI
Lymphoma development in the elderly: Perturbed posttranscriptional regulation$0
I01 · FY2016 · VA · contact PI
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm$345,726
R01 · FY2015 · CA
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm$335,991
R01 · FY2014 · CA
MEK/ERK pathways and MCT-1 in Diffuse Large B-cell Lymphoma$0
I01 · FY2014 · VA · contact PI
Alcohol Consumption and Risk of NHL: Role of MTOR Dysfunction$315,273
R01 · FY2013 · AA · contact PI
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm$311,368
R01 · FY2013 · CA
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm$16,858
R01 · FY2013 · CA
MEK/ERK pathways and MCT-1 in Diffuse Large B-cell Lymphoma$0
I01 · FY2013 · VA · contact PI
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm$373,508
R01 · FY2012 · CA
Alcohol Consumption and Risk of NHL: Role of MTOR Dysfunction$339,003
R01 · FY2012 · AA · contact PI
MEK/ERK pathways and MCT-1 in Diffuse Large B-cell Lymphoma$0
I01 · FY2012 · VA · contact PI
Alcohol Consumption and Risk of NHL: Role of MTOR Dysfunction$339,003
R01 · FY2011 · AA · contact PI
MEK/ERK pathways and MCT-1 in Diffuse Large B-cell Lymphoma$0
I01 · FY2011 · VA · contact PI
Alcohol Consumption and Risk of NHL: Role of MTOR Dysfunction$352,688
R01 · FY2010 · AA · contact PI
Alcohol Consumption and Risk of NHL: Role of MTOR Dysfunction$356,250
R01 · FY2009 · AA · contact PI